報價延遲最少15分鐘:2026/04/15 15:07 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.14 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.00/-0.69
|
|
企業價值
41.48M
|
| 資產負債 |
|
每股賬面淨值
2.04
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.53M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options. |
